A terhesség alatti hüvelyi natamycin-kezelés eset-kontroll teratológiai vizsgálata

Translated title of the contribution: A case-control teratological study of vaginal natamycin treatment during pregnancy

Zoltán Kazy, Péter Vargha, E. Czeizel

Research output: Contribution to journalArticle

Abstract

The aim of this study was to investigate the teratogenicity of vaginal natamycin treatment during pregnancy. Data of human epidemiological studies have not been published so far. Pair analysis of cases with congenital anomalies and matched healthy controls was carried out. The population-based data set of the Hungarian Case-Control Surveillance of Congenital Abnormalities between 1980 and 1996 included 38,151 pregnant women who delivered newborn infants without any congenital defects (control group) and 22,843 pregnant women who had fetuses or newborns with congenital abnormalities. 62 (0.27%) and 98 (0.26%) pregnant women were treated with natamycin in the case and the control group, respectively (crude OR 1.1 with 95% CI: 0.8-1.5). A teratogenic potential of vaginal natamycin treatment during the second and third months of pregnancy, the critical period for most major congenital abnormalities, was not indicated in the case-control pair analysis (adjusted OR 0.9 with 95% CI: 0.4-1.8). A somewhat higher mean birth weight (72 g) was found in the control newborn infants born to mothers who have had natamycin treatment as compared to the data of control newborn infants without this treatment (adjusted p=0.01), though the mean gestational age was shorter. From this study we may conclude that treatment with vaginal natamycin during pregnancy presents no detectable teratogenic risk for the fetus.

Original languageHungarian
Pages (from-to)219-224
Number of pages6
JournalMagyar Noorvosok Lapja
Volume67
Issue number4
Publication statusPublished - 2004

Fingerprint

Natamycin
Case-Control Studies
Pregnancy
Newborn Infant
Pregnant Women
Fetus
Therapeutics
Control Groups
Birth Weight
Gestational Age
Epidemiologic Studies
Mothers
Population

ASJC Scopus subject areas

  • Obstetrics and Gynaecology

Cite this

A terhesség alatti hüvelyi natamycin-kezelés eset-kontroll teratológiai vizsgálata. / Kazy, Zoltán; Vargha, Péter; Czeizel, E.

In: Magyar Noorvosok Lapja, Vol. 67, No. 4, 2004, p. 219-224.

Research output: Contribution to journalArticle

@article{221be78fd76248de9b29989caae1ddde,
title = "A terhess{\'e}g alatti h{\"u}velyi natamycin-kezel{\'e}s eset-kontroll teratol{\'o}giai vizsg{\'a}lata",
abstract = "The aim of this study was to investigate the teratogenicity of vaginal natamycin treatment during pregnancy. Data of human epidemiological studies have not been published so far. Pair analysis of cases with congenital anomalies and matched healthy controls was carried out. The population-based data set of the Hungarian Case-Control Surveillance of Congenital Abnormalities between 1980 and 1996 included 38,151 pregnant women who delivered newborn infants without any congenital defects (control group) and 22,843 pregnant women who had fetuses or newborns with congenital abnormalities. 62 (0.27{\%}) and 98 (0.26{\%}) pregnant women were treated with natamycin in the case and the control group, respectively (crude OR 1.1 with 95{\%} CI: 0.8-1.5). A teratogenic potential of vaginal natamycin treatment during the second and third months of pregnancy, the critical period for most major congenital abnormalities, was not indicated in the case-control pair analysis (adjusted OR 0.9 with 95{\%} CI: 0.4-1.8). A somewhat higher mean birth weight (72 g) was found in the control newborn infants born to mothers who have had natamycin treatment as compared to the data of control newborn infants without this treatment (adjusted p=0.01), though the mean gestational age was shorter. From this study we may conclude that treatment with vaginal natamycin during pregnancy presents no detectable teratogenic risk for the fetus.",
keywords = "Birth weight, Case-control study, Congenital abnormalities, Human teratogenic potential, Natamycin",
author = "Zolt{\'a}n Kazy and P{\'e}ter Vargha and E. Czeizel",
year = "2004",
language = "Hungarian",
volume = "67",
pages = "219--224",
journal = "Magyar Noorvosok Lapja",
issn = "0025-021X",
publisher = "Magyar Noovos Tarsasag",
number = "4",

}

TY - JOUR

T1 - A terhesség alatti hüvelyi natamycin-kezelés eset-kontroll teratológiai vizsgálata

AU - Kazy, Zoltán

AU - Vargha, Péter

AU - Czeizel, E.

PY - 2004

Y1 - 2004

N2 - The aim of this study was to investigate the teratogenicity of vaginal natamycin treatment during pregnancy. Data of human epidemiological studies have not been published so far. Pair analysis of cases with congenital anomalies and matched healthy controls was carried out. The population-based data set of the Hungarian Case-Control Surveillance of Congenital Abnormalities between 1980 and 1996 included 38,151 pregnant women who delivered newborn infants without any congenital defects (control group) and 22,843 pregnant women who had fetuses or newborns with congenital abnormalities. 62 (0.27%) and 98 (0.26%) pregnant women were treated with natamycin in the case and the control group, respectively (crude OR 1.1 with 95% CI: 0.8-1.5). A teratogenic potential of vaginal natamycin treatment during the second and third months of pregnancy, the critical period for most major congenital abnormalities, was not indicated in the case-control pair analysis (adjusted OR 0.9 with 95% CI: 0.4-1.8). A somewhat higher mean birth weight (72 g) was found in the control newborn infants born to mothers who have had natamycin treatment as compared to the data of control newborn infants without this treatment (adjusted p=0.01), though the mean gestational age was shorter. From this study we may conclude that treatment with vaginal natamycin during pregnancy presents no detectable teratogenic risk for the fetus.

AB - The aim of this study was to investigate the teratogenicity of vaginal natamycin treatment during pregnancy. Data of human epidemiological studies have not been published so far. Pair analysis of cases with congenital anomalies and matched healthy controls was carried out. The population-based data set of the Hungarian Case-Control Surveillance of Congenital Abnormalities between 1980 and 1996 included 38,151 pregnant women who delivered newborn infants without any congenital defects (control group) and 22,843 pregnant women who had fetuses or newborns with congenital abnormalities. 62 (0.27%) and 98 (0.26%) pregnant women were treated with natamycin in the case and the control group, respectively (crude OR 1.1 with 95% CI: 0.8-1.5). A teratogenic potential of vaginal natamycin treatment during the second and third months of pregnancy, the critical period for most major congenital abnormalities, was not indicated in the case-control pair analysis (adjusted OR 0.9 with 95% CI: 0.4-1.8). A somewhat higher mean birth weight (72 g) was found in the control newborn infants born to mothers who have had natamycin treatment as compared to the data of control newborn infants without this treatment (adjusted p=0.01), though the mean gestational age was shorter. From this study we may conclude that treatment with vaginal natamycin during pregnancy presents no detectable teratogenic risk for the fetus.

KW - Birth weight

KW - Case-control study

KW - Congenital abnormalities

KW - Human teratogenic potential

KW - Natamycin

UR - http://www.scopus.com/inward/record.url?scp=3542995104&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3542995104&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:3542995104

VL - 67

SP - 219

EP - 224

JO - Magyar Noorvosok Lapja

JF - Magyar Noorvosok Lapja

SN - 0025-021X

IS - 4

ER -